Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

PubWeight™: 1.53‹?› | Rank: Top 4%

🔗 View Article (PMID 25589614)

Published in Clin Cancer Res on January 14, 2015

Authors

Liang Zhang1, Xiaoen Wang1,2, Andrea J Bullock1, Marcella Callea3, Harleen Shah4, Jiaxi Song3, Kelli Moreno5, Barbara Visentin5, Douglas Deutschman6, David C Alsop2, Michael B Atkins7, James W Mier1, Sabina Signoretti3, Manoj Bhasin4, Roger A Sabbadini5, Rupal S Bhatt1

Author Affiliations

1: Division of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts, 02215, United States of America.
2: Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts, 02215, United States of America.
3: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts, 02115, United States of America.
4: Division of Interdisciplinary Medicine and Biotechnology, and Genomics and Proteomics Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts, 02215, United States of America.
5: Lpath Inc., 4025 Sorrento Valley Blvd. San Diego, CA, 92121, United States of America.
6: Department of Biology, San Diego State University, 5500 Campanile Dr. San Diego, CA. 92182-4614, United States of America.
7: Departments of Oncology and Medicine, Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, NW, Washington, DC. United States of America.

Articles cited by this

Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58

Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 5.01

Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab (1996) 4.30

Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13

Sphingosine 1-phosphate and cancer. Nat Rev Cancer (2010) 3.95

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44

Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41

An oncogenic role of sphingosine kinase. Curr Biol (2000) 2.59

Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med (2009) 2.34

Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol (2005) 2.32

Relaxation response induces temporal transcriptome changes in energy metabolism, insulin secretion and inflammatory pathways. PLoS One (2013) 2.05

Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05

Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01

Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer (2008) 1.62

Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res (2009) 1.59

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer (2013) 1.57

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med (2014) 1.43

Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology (2009) 1.42

Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res (2011) 1.38

Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem (2007) 1.36

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32

Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J Biol Chem (2003) 1.31

Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res (2009) 1.29

Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol (2010) 1.28

Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res (2008) 1.23

Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol (2011) 1.16

Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther (2010) 1.10

Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. Cell Physiol Biochem (2010) 1.02

Cell type-specific localization of sphingosine kinase 1a in human tissues. J Histochem Cytochem (2001) 1.02

First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther (2012) 0.97

Subtype-specific, differential activities of the EDG family receptors for sphingosine-1-phosphate, a novel lysophospholipid mediator. Mol Cell Endocrinol (2001) 0.95

Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front Oncol (2012) 0.92

Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol (2010) 0.88

Increased SPHK1 expression is associated with poor prognosis in bladder cancer. Tumour Biol (2013) 0.86

Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One (2009) 0.86

Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. Adv Cancer Res (2013) 0.86

Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci (2012) 0.83

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann Oncol (2013) 0.83

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol (2014) 0.82

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer. J Cancer Res Clin Oncol (2013) 0.81

Lysophosphatidic acid and sphingosine 1-phosphate metabolic pathways and their receptors are differentially regulated during decidualization of human endometrial stromal cells. Mol Hum Reprod (2014) 0.78